ARCA biopharma Announces Second Quarter 2018 Financial Results and Provides Corporate Update

Author's Avatar
Aug 10, 2018
Article's Main Image

End-of-Phase 2 Meeting with the U.S. FDA on Gencaro Atrial Fibrillation Development Plan Completed; Single Additional Phase 3 Trial Planned to Support NDA Submission